camurus®

Company Presentation

Cowen & Co. 40th Annual Health Care Conference
2 March 2020, Boston, MA

Forward looking statements

This presentation contains forward-looking statements that provide our expectations or forecasts of future events such as new product developments and regulatory approvals and financial performance.

Camurus is providing the following cautionary statement. Such forward-looking statements are subject to risks, uncertainties and inaccurate assumptions. This may cause actual results to differ materially from expectations and it may cause any or all of our forward-looking statements here or in other publications to be wrong. Factors that may affect future results include currency exchange rate fluctuations, delay or failure of development projects, loss or expiry of patents, production problems, unexpected contract, patent, breaches or terminations, government-mandated or market-driven price decreases, introduction of competing products, Camurus' ability to successfully market products, exposure to product liability claims and other lawsuits, changes in reimbursement rules and governmental laws and interpretation thereof, and unexpected cost increases.

Camurus undertakes no obligation to update forward-looking statements

Camurus in brief

LISTED ON NASDAQ STO; TICKER **CAMX** MARKET CAP
~ SEK 4.5 billion EMPLOYEES: **130** HQ: **Lund, Sweden**
REG. OFFICES: **Cambridge, Mannheim, Sydney, Paris**

Unique FluidCrystal® nanotechnologies

- In-house developed with strong IP
- New generation long-acting depot technology
- Validated in 20 clinical trials and by approved products

Two Phase 3 programs

- Late-stage pipeline with 10 innovative clinical programs in addiction, pain, oncology, endocrine and CV disease
- Growing early stage opportunities

Approved medicines

Weekly and monthly Buvidal® for the treatment of opioid dependence

Own commercial organization

Fully operational in Europe and Australia

Partnerships

R&D collaborations, licensing and royalty arrangements with numerous companies

Experienced management and dedicated teams

Operational highlights 2019

- **Buvidal® launch** initiated in EU (Finland, Sweden, Germany, UK and Denmark)
  - **Rights issue** SEK 403 million
  - **Publication** of Buvidal® Phase 3 long-term safety data in *Addiction*
  - **CAM2038** chronic pain **Phase 3 safety** study completed
- **CAM2029 Phase** 3 **study** initiated in acromegaly
  - License agreement with **Ra Pharma** for long-acting zilucoplan
  - **DEBUT and UNLOC-T** clinical trials fully enrolled and successfully completed
- **Buvidal launched in** Norway and Australia
  - Start of CAM2029 **Phase 3 long-term safety study**
  - Buvidal® receives **pricing and reimbursement** in key markets
- Buvidal® NDA filed in **New Zealand**
- FDA **grants Citizen Petition** allowing Brixadi™ on the US market in Dec 2020
  - **Directed share issue** SEK 300 million
- **Superior patient outcomes** received in DEBUT RCT
  - Partnership with **NewBridge** for Buvidal in 12 MENA countries

2019 2020

camurus.

Buvidal® / Brixadi™

Individualized weekly and monthly treatment for opioid dependence

Opioid dependence – escalating global health crisis

- **Largest society burden of all drugs[1]**
- **35 million opioid users worldwide[1]**
- **High need for better access to care and new treatment alternatives**
- **Investment in treatment brings substantial value and saves lives**
- **Significant limitation with current daily medications**
  - Diversion, misuse, overdosing, poor retention, burdens and stigma of daily buprenorphine and methadone medications

camurus.

Mounting opioid overdose deaths[2]



#1 cause of death for people under 50 in the US[2,3]

Recent US life expectancy decline largely due to opioids[4]

Sources: [1]UNODC, World Drug Report 2019; [2]EMCDDA 2018, National Records of Scotland, Centers for Disease Control and Prevention [3]Frazier at al, 2017, Journal of the American Medical Association; [4]Crow D. Financial Times.com, accessed on March 13, 2018, https://www.ft.com/content/d22e742c-e65c-11e7-97e2-916d4fbac0da

Buvidal® – first long-acting treatment of opioid dependence in the EU and Australia

Flexible-dose, weekly and monthly, subcutaneous buprenorphine for **treatment of opioid dependence** within a framework of medical, social and phychological treatment in adults and adolescents 16 years or over[1]

Source: [1]Buvidal Summary of Product Characteristics (SmPC), 2018

Buvidal brings significant values over daily medications

✓ **Less burden and stigma for patients**	• Improved convenience and quality of life • Ability to live a more normal life
✓ **Safeguard against misuse overdosing and diversion**	• Continuous blockade of effect of illicit opioids • Healthcare professional administration safeguards against diversion, misuse and pediatric exposure
✓ **Demonstrated improved treatment outcomes**	• Superiority versus standard of care with daily sublingual buprenorphine medications • High retention in clinical trials and real worlds settings
✓ **Suitable for patients across treatment phases**	• Individualized dosing for use across treatment phases: initiation, switching from daily medications and long-term maintenance treatment

Objective: Establish Buvidal as a new standard of care in opioid dependence

Source: Buvidal Summary of Product Characteristics (SmPC), 2018

Buvidal is well positioned against the competition

Long-acting injection treatments for opioid dependence

PRODUCT	WEEKLY DOSING	MONTHLY DOSING	MULTIPLE DOSES	CHOICE OF INJECTION SITES	SMALL NEEDLE	LOW VOLUMES	ROOM TEMP. STORAGE	DAY ONE INITIATION	CLIN. DATA VS ACTIVE CONTROL*	LAUNCHED
Weekly/Monthly Buvidal BUPRENORPHINE PROLONGED-RELEASE SOLUTION FOR INJECTION	✓	✓	✓	✓	✓ 23G	✓ 0.16 – 0.64 mL	✓	✓	✓	EU, AUSTRALIA
Sublocade (buprenorphine extended-release) injection for subcutaneous use 100mg·300mg	—	✓	—	—	— 19G	— 0.5 – 1.5 mL	—	—	—	US
Vivitrol (naltrexone for extended-release injectable suspension)	—	✓	—	—	— 20G	— 3.4 mL	—	—	—	US

*Based on information in product labels

Camurus' global strategy for Buvidal® (Brixadi™)

	REGION	PARTNER	NO OF PATIENTS	PEAK MARKET POTENTIAL
	EU Australia	camurus.	**~1.3 million** HIGH-RISK OPIOID USERS[1]	**~€300 million**[2]
	North America	braeburn	**>2 million** DIAGNOSED WITH OPIOID USE DISORDER IN THE US[3]	**$0.6-1.2 billion**[4, 5]
	Middle East & North Africa	NEWBRIDGE PHARMACEUTICALS MEDISON (Israel) Delivering Innovative Healthcare	**>300,000** WITH OPIOID DEPENDENCE[6]	**€25-75 million**[5]

Source: [1]European Drug Report 2019; [2]Camurus estimate; [3]SAMHSA, Results from the 2017 National Survey on Drug Use and Health, Sep. 2018; [4]Opioid Use Disorder: Opportunity Analysis and Forecasts to 2027, GlobalData 2018; [5]Camurus estimates; [6]World Drug Report and NewBridge estimate;

Buvidal launch continues in EU & Australia



Launch sequence

- Wave 1 markets
- Wave 2 markets
- Wave 3 markets
- Wave 4 expansion

Launched in seven Wave 1 markets in 2019

- ✓ Finland, Sweden, Germany, UK and Denmark during Q1 2019
- ✓ Australia and Norway in Q3 2019 after pricing and reimbursement listings

2020 market expansion in Wave 2-3 markets

- ✓ Launches planned in Austria, Spain, Italy, Benelux, and other EU countries following market access approvals
- ✓ MENA region through partnership with NewBridge

Strong Buvidal finish in 2019 lays foundation for continued growth during 2020

Buvidal 2019 key takeaways

- ✓ Exceptional start in Finland with >40% BPN share in 12 months
- ✓ Strong start in Norway and Australia
- ✓ Accelerating uptake in Germany, Sweden, Denmark and UK
- ✓ 4000 patients in treatment at end of 2019
- ✓ Very positive response from patients and HCPs
- ✓ High retention in treatment, estimated 80-90% in first year

Initial product sales 2019



Buvidal 2020 strategy

- Increase market share and patient base in Wave 1 markets
- Expand to new geographies
- Establish Buvidal as preferred treatment choice

Sales guidance	FY 2020 MSEK
– Buvidal product sales	240 – 280

Brixadi™ – significant opportunity in the US

- **Tentative approval** 21 Dec. 2018
- FDA has granted Citizen Petition and revoked the orphan designation for Sublocade™
- **Clear path to final approval** on Dec 1, 2020
  - Triggers $35m approval milestone for OUD
  - $70m in sales milestones
  - Mid teen royalty on net product sales
- **All product requirements in place** for a successful launch
- Strategy addresses the **need for reliable, easy access to an effective treatment** of OUD
- **Double-digit market growth** and urgent need for high-quality treatments of OUD

~40% of US oral buprenorphine prescriptions are 7 days or less[1]



Source: 1. Symphony Health Patient Source, 2017

New studies demonstrate benefits and superiority of Buvidal® versus standard treatments

DEBUT – Depot Evaluation Buprenorphine Utilization Trial

- Randomized, open-label, active-controlled study of Buvidal vs standard of care in 120 adult outpatients with opioid dependence
- **Study met both primary and secondary objectives**
  - Superior TSQM global satisfaction, p=0.0143
  - Significantly higher TSQM effectiveness and convenience domain scores, p<0.0001

UNLOC-T – Safety and feasibility of depot buprenorphine in New South Wales custodial settings

- Prospective, non-randomized, open-label, multicenter study in 129 OUD patients treated with Buvidal or methadone in eight prisons.
- Primary objective to test safety, tolerability, diversion and HEOR
- Secondary objectives to compare efficacy and QoL
- **Positive preliminary results in Q4 2019;** resulted in resource allocation and scale-up in NSW prisons



Strong and growing Buvidal® evidence base presented at conferences and in journals

Conferences where Buvidal data will be presented during 2020

2020	Q1	Q2	Q3	Q4
Global Conferences		ASAM 2-5 Apr Denver, USA; CPDD 20-24 Jun Hollywood, FL	ISAM 13-16 Nov Victoria, Canada	AAAP 10-13 Dec San Antonio, USA
European Conferences		IOTOD 18-19 May Amsterdam, NL; ALBATROS 10-12 Jun Paris, France; EUROPAD 29-31 May Grenoble, France	Nord Op Sym 1-2 Oct Uppsala, Sweden	
National Conferences	Encephate 22-24 Jan Paris, France; SFA 12-13 Mar Paris, France; RCGP MDAP 30-31 Jan London, UK; F Add Psych Apr London, UK; J Sociodrog 5-7 Mar Madrid, Spain; Fin S Add Med 5-6 Mar Helsinki, Finland	SEPD 21-23 May Seville, Spain; K f Suchtmed 2-4 Jul Munich, Germany; S Esp San Pen 7-9 May Madrid, Spain; Subforum 9-10 May Mondsee, Aut	LAR konf 15-16 Oct Oslo, Norway; DGS konf 30 Oct-1 Nov Berlin, Germany; FederSerD Oct Milan, Italy	SAD 5-6 Nov Uppsala, Sweden; SSA 5-6 Nov Newcastle, UK; SiPaD Nov Rome, Italy; APSAD 15-18 Nov Brisbane, Aus

Key publications[1-5]


ADDICTION
RESEARCH REPORT
Long-term safety of a weekly and monthly subcutaneous buprenorphine depot (CAM2038) in the treatment of adult out-patients with opioid use disorder
JAMA Internal Medicine | Original Investigation
Weekly and Monthly Subcutaneous Buprenorphine Depot Formulations vs Daily Sublingual Buprenorphine With Naloxone for Treatment of Opioid Use Disorder
A Randomized Clinical Trial
JAMA Psychiatry | Original Investigation
Effect of Buprenorphine Weekly Depot (CAM2038) and Hydromorphone Blockade in Individuals With Opioid Use Disorder
A Randomized Clinical Trial
Pharmacokinetic Evaluation of Once-Weekly and Once-Monthly Buprenorphine Subcutaneous Injection Depots (CAM2038) Versus Intravenous and Sublingual Buprenorphine in Healthy Volunteers Under Naltrexone Blockade: An Open-Label Phase 1 Study
Pharmacokinetics and pharmacodynamics of a buprenorphine subcutaneous depot formulation (CAM2038) for once-weekly dosing in patients with opioid use disorder
Journal of Substance Abuse Treatment

[1]Lofwall et al. JAMA Int. Med. 2018;178(6); 764-773; [2]Frost et al, Addiction, 2019;114(8):1416-1426, [3]Walsh et al, JAMA Psychiatry 2017;74(9):894-902; [4]Haasen, C, et al, J Subst Abuse Treat. 2017;78:22-29; [5]Albayaty M, et al, Adv Ther. 2017 34(2):560-575

Broad and late-stage pipeline



1. Braeburn holds the rights to North America; 2. Developed by Rhythm Pharmaceuticals under a worldwide license to FluidCrystal®;
3. Chemotherapy-induced nausea and vomiting; 4. Postoperative nausea and vomiting;


camurus.
CAM2029
Improving lives of patients with neuroendocrine and pituitary disorders

Significant potential for CAM2029 in somatostatin analogue market

Sandostatin® LAR® (octreotide) and Somatuline® Autogel® (lanreotide) are first-line medical therapy in acromegaly and NET

~67,000

ACROMEGALY & NET PATIENTS TREATED WITH SSAs IN US / EU5[2]



US$ 2.7 billion

CURRENT SSA MARKET VALUE[1,3]



Significant limitations of current SSA treatments

Difficult handling & administration

- Need for regular visits at specialty clinics or home nursing
- IM or deep SC dosing, complex handling in multiple steps
- Large bore needles

Sub-optimal treatment response

- Significant room for improving efficacy; disease biomarkers in acromegaly and symptom and tumor control in NETs

CAM2029, octreotide SC depot, offers clear differentation and addresses the key market unmet needs

✓ **Simplified administration**

✓ **Potential for self-administration**

- Ready-to-use prefilled syringe and autoinjector for enhanced convenience with option to self-administer

✓ **Potential for improved biochemical and symptom control**

- Limited response with current SSA treatments in acromegaly; ~25-45% biochemical control[3,4]
- Significant room for improvement of symptom and tumor control in patients with GI- NET

- Fast onset and long-acting release with 500% higher bioavailibility vs octreotide LAR[1]
- Well maintained or improved biochemical and symptom control indicated with CAM2029 in acromegaly and NET patients[2]

Strategy: Position CAM2029 as the gold standard somatostatin analogue across acromegaly and NET, offering **the most convenient and effective treatment option**

Source: [1]Tiberg F, Br J Clin Pharmacol. 2015 Sep;80(3):460-72; [2.]Pavel M et al, Cancer Chemotherapy and Pharmacology 2019; 83:375–385; [3]Carmichael JD, et al., J Clin Endocrinol Metab. 2014 May;99(5):1825-33; [4]Melmed S, et al., Nat Rev Endocrinol. 2018 Sep;14(9):552-561

Phase 2 study indicates improved biochemical and symptom control when switching from Sandostatin® LAR to CAM2029

IGF-1 in acromegaly patients



Flushing and diarrhea in NET patient



Analysis of data from Pavel M et al, Cancer Chemotherapy and Pharmacology, 2019; 83(2): 375–385
GH, growth hormone; IGF-1, insulin-like growth factor 1; LAR, long-acting release; NET, neuorendocrine tumors

External market assessment estimates blockbuster sales potential for CAM2029[1]





Scenario 1
CAM2029 is available as a **pre-filled syringe** (PFS) device with equivalent efficacy to current long-acting SSAs, with an assumed penetration of 10–20% in Acromegaly, and 10–15% in NET

Scenario 2
Available both as PFS and as an **autoinjector**, with equivalent efficacy to current long-acting SSAs and an assumed penetration of 20–25%

Scenario 3 – TARGET
Available both as PFS and as an **autoinjector**, with data suggesting **superior efficacy** over current long-acting SSAs, and an assumed higher penetration of 30–35%

Estimated potential peak sales range $300m – $1,260m, depending on product profile

Source: 1. Globe Life Sciences reports 2019; data on file

Phase 3 programs initiated for CAM2029

Four clinical trials completed in healthy subjects and patients characterizing PK, PD and safety profile (N=249)



ACRO Phase 3 PC	ACRO Phase 3 LTSE	Autoinjector PK	NET Phase 3
Randomized, double-blind, placebo-controlled study in SSA responders	Open-label, long-term safety study in partial and full responders	PK bridging study of prefilled syringe and autoinjector devices	Active controlled Phase 3 study in patients with metastatic, well differen-tiated GEP-NET

Progress in partnerships

Rhythm: Genetic disorders of obesity

- **Setmelanotid FluidCrystal weekly SC depot**
  - Treatment of POMC deficiency, LEPR deficiency, and Bardet-Biedl syndrome obesity
- **Phase 1b clinical milestone achieved**
  - Plasma half-life ~120 hours[1]
  - Good overall tolerability
- **Dose escalating Phase 2 study in more than 70 obese HVs under completion[1]**
- **Positive Phase 3 data announced for daily setmelanotide in POMC / LEPR deficiency Aug. 2019[2]**

Ra Pharma: Complement-mediated disorders

- **Zilucoplan FluidCrystal SC depot**
  - Treatment of generalized myasthenia gravis (gMG), immune-mediated necrotizing myopathy (IMNM), and other serious complement C5 mediated disorders
- **Preclinical PoC**
- **License agreement signed July 2019**
- **Clinical development planned for H2 2020**
- **UCB to acquire Ra Pharma for $2.5 billion, Oct. 2019[3]**



Inhibition of hemolysis following a single dose of zilucoplan FluidCrystal® in cynomolgus monkeys (n=4)

Source: [1]Rhythm Corporate Presentation – January 2020 https://ir.rhythmtx.com/static-files/38f3b5c8-4b34-4fde-935a-2d041bf20696; [2]Press release Rhythm Pharmaceuticals 7 August 2019; [3]Press release UCB and Ra Pharmaceuticals 10 October 2019

Multiple levers for continued growth and value creation on short and medium term

- Establish **leadership in opioid dependence treatment** in EU and Australia
- **Market expansion** in EU and RoW through own organization and partners
- **US approval and launch of Brixadi** by Braeburn
- Further expand the **robust scientific evidence base for Buvidal**

- Drive **late-stage development and obtain new regulatory approvals** in chronic pain, acromegaly and neuroendocrine tumors
- Advance our **early pipeline of innovative medicines** in areas of high unmet medical need and large market potential

- Expand **utilization of FluidCrystal technology platform** to new products through own developments and partnerships
- Build **a world-class commercial organization** in the EU and Australia
- Develop **sustained profitability** through own sales, partnerships, and business development



Thank You

Camurus AB, Ideon Science Park, SE-223 70 Lund, Sweden
info@camurus.com **camurus.com**

Outlook 2020 – tentative milestones and times

- **Buvidal® launch expansion** to 2nd and 3rd wave countries
  - Start **Phase 2a** study of **CAM2043** in Raynaud's
  - **Bridging PK study** of CAM2029 in AI and PFS devices
  - **Start sales in the MENA region**
- Planned **regulatory submission** of CAM2038 in chronic pain
  - **Data from Phase 2a** study of CAM4072
  - **Long-acting zilucoplan** CAM4083 clinical program
  - **Phase 2a** results for **CAM2043** in Raynaud's
- **US NDA approval of Brixadi™** in opioid use disorder
- **Brixadi™** launch in the US
- **Completed enrollment** in Phase 3 acromegaly studies
- **Initiation of Phase 3 NET program**

2020 | 2021

Consolidated statement Q4 and FY 2019

KSEK	Q4 2019 2019 Oct-Dec	Q4 2019 2018 Oct-Dec	Q4 2019 % change	FY 2019 2019 Jan-Dec	FY 2019 2018 Jan-Dec	FY 2019 % change
Net revenues	35,023	7,805	349%	105,605	49,321	114%
Cost of goods sold	-13,540	-3,937		-23,287	-6,822	
Gross profit	**21,483**	**3,868**	455%	**82,318**	**42,499**	94%
Marketing and distribution costs	-41,905	-39,547		-170,54	-100,884	
Administrative expenses	-5,601	-6,212		-23,468	-21,999	
Research and development costs	-63,205	-61,863		-249,226	-207,664	
Other operating income	817	565		894	830	
Other operating expenses						
Operating results	**-88,411**	**-103,189**	14%	**-360,022**	**-287,218**	-25%
Finance income	21	59		43	175	
Finance expenses	-346	-3		-1,585	-25	
Net financial items	**-325**	**56**		**-1,542**	**150**	
Result before tax	**-88,736**	**-103,133**	14%	**-361,564**	**-287,068**	-26%
Income tax	16,880	15,986		71,699	52,392	
Result for the period	**-71,856**	**-87,147**	18%	**-289,865**	**-234,676**	-24%

Outlook 2020

- **Total net revenues** are expected to grow to **290-330 million SEK** (excl. milestone payments relating to Brixadi approvals in the US) primarily due to increasing Buvidal sales.
- **Product sales** are expected to grow to between **240-280 million SEK**, due to increasing Buvidal market shares and treatment expansion in our first wave markets in Europe and Australia and geographic expansion to second and third wave markets.
- **OPEX** is expected to increase to between **570-610 million SEK** primarily due to increasing investments in the Phase 3 programs in acromegaly and NET, market preparations for CAM2038 in chronic pain, and expansion of our commercial organization and activities.

Shareholders

Shareholders as of 31 January 2020	Number of shares	% of capital	% of votes
Sandberg Development AB	22,200,692	43.0	43.0
Gladiator	4,078,558	7.9	7.9
Fjärde AP-fonden	3,250,676	6.3	6.3
Fredrik Tiberg, CEO	1,703,188	3.3	3.3
Avanza Pension	1,508,285	2.9	2.9
Backahill Utveckling	1,176,491	2.3	2.3
Catella Fondförvaltning	1,062,570	2.1	2.1
Svenskt Näringsliv	725,000	1.4	1.4
Camurus Lipid Research Foundation	505,250	1.0	1.0
Nordnet Pensionsförsäkring	452,480	0.9	0.9
Enter fonder	437,561	0.8	0.8
Carl-Olof och Jenz Hamrins Stiftelse	425,000	0.8	0.8
Grenspecialisten Förvaltning	420,870	0.8	0.8
SEB Investment Management	349,018	0.7	0.7
Lancelot Asset Management	325,000	0.7	0.7
Other shareholders	13,016,219	25.2	25.2
In total	**51,636,858**	**100.0**	**100.0**

Shareholder distribution



Experienced and committed management team

Fredrik Tiberg, PhD
President & CEO

In Company since: *2002*
Holdings: *1,703,188 shares & 220,000 warrants*

Education: M.Sc. in Chemical Engineering, PhD in Physical Chemistry, Lund University

Previous experience: Professor in Physical Chemistry at Lund University, Visiting Professor at Oxford University, Institute for Surface Chemistry (Section head),

Cecilia Callmer
Vice President, Human Resources

In Company since: *2017*
Holdings: *26,000 warrants*

Torsten Malmström, PhD
Chief Technical Officer

In Company since: *2013*
Holdings: *45,363 shares & 8,000 subscription warrants*

Eva Pinotti-Lindqvist
Chief Financial Officer

In Company since: *2014*
Holdings: *45,363 shares & 22,891 warrants*

Education: Bachelor's of Science in Economics, Lund University

Previous experience: EQL Pharma (CFO), Nordic Drugs (Nordic Market Analyst), Poolia (Finance Consultant)

Fredrik Joabsson, PhD
Chief Business Development Officer

In Company since: *2001*
Holdings: *45,463 shares & 45,000 warrants*

Annette Mattsson
Vice President, Regulatory Affairs

In Company since: *2017*
Holdings: *375 shares & 25,000 subscription warrants*

Richard Jameson
Chief Commercial Officer

In Company since: *2016*
Holdings: *20,490 shares & 80,000 warrants*

Education: Bachelor's of Science in Applied Biological Sciences from University West of England

Previous experience: GM, UK and Nordics for Reckitt Benckiser Pharmaceuticals Ltd (2010 – 2013) and Area Director Europe, Middle East and Africa for Indivior PLC (2013 – 2016).

Urban Paulsson
Vice President Corporate Dev.& General Counsel

In Company since: *2017*
Holdings: *8,125 shares & 115,000 warrants*

Agneta Svedberg
Vice President, Clinical & Regulatory Development

In Company since: *2015*
Holdings: *11,341 shares & 75,000 subscription warrants*